-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Names & News
-
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case.
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
-
Breaking the Silence: The #HearHer Campaign for Women with Lung Cancer
Narjust Florez, MD, and Angela Morabito, BS, launched the #HearHer campaign to raise awareness about the increasing incidence of lung cancer among women and the frequent delays in diagnosis.
-
Oncology Trialists and Their Minions
Poet and ILCN Editor-in-Chief Corey Langer, MD, illustrates the build-up and anticipation surrounding the release of research data.
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care.
-
Laura Greco of “Die, Cancer, Die!” Fame will be Remembered for her Passionate Patient Advocacy
The legacies patients like Ms. Greco leave serve to remind the thoracic oncology community why its work is vital.
-
Patient Advocate Ivy B. Elkins Leaves Lasting Legacy
Ms. Elkins, co-founder of the EGFR Resisters advocacy group, will be remembered for her warm and energetic approach to furthering lung cancer research efforts.
-
IASLC Names New Chief Science Officer
Dr. Jennifer King brings expertise in molecular targets for cancer therapeutics as well as executive-level experience implementing strategic initiatives to the scientific affairs team.
-
In Brief for July 26, 2023
IASLC Hot Topic meeting to feature keynote address on resistance to immunotherapy by Dr. Drew Pardoll. Lung Cancer Research Foundation announces appointment of new executive director Aubrey Rhodes.